<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">EXENATIDE</span><br/>(e-xe'na-tide)<br/><span class="topboxtradename">Byetta<br/></span><b>Classifications:</b> <span class="classification">antidiabetic agent, integrin mimetic</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mcg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Improves glycemic control in people with type 2 diabetes mellitus by mimicking the functions of incretin, a glucagon-like
         peptide-1 (GLP-1). Exenatide enhances glucose-dependent insulin secretion by pancreatic beta-cells, suppresses inappropriately
         elevated glucagon secretion, and slows gastric emptying. These actions decrease glucagon stimulation of hepatic glucose output
         and decrease insulin demand. 
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Improves glycemic control by reducing fasting and postprandial glucose concentrations in patients with type 2 diabetes.</p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct treatment of type 2 diabetes mellitus in those inadequately managed by metformin, a sulfonylurea, or a combination
         of these agents.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Type 2 Diabetes Mellitus</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> Initial dose of 5 mcg b.i.d., within 60 min prior to the morning and evening meal. After 1 mo. may increase to 10 mcg b.i.d.,
               within 60 min prior to the morning and evening meal.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>Give SC into thigh, abdomen, or upper arm within 60 min before the morning and evening meals. Do not administer after a meal.</li>
<li>Do not give within 1 h of oral antibiotics, an oral contraceptive, or acetaminophen.	</li>
<li>Store at 36°46° F (2°8° C) and protect from light. Discard pen 30 d after first use. Do not
            use if pen has been frozen. 
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Asthenia, dizziness, restlessness, jittery feeling. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea, dyspepsia, anorexia, gastroesophageal reflux. <span class="typehead">Metabolic:</span> Hypoglycemia, excessive sweating (hyperhidrosis or diaphoresis).  
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Due to its ability to slow gastric emptying, exenatide can decrease the rate and/or serum levels of oral medications that
      require GI absorption. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Peak:</span>  2 h. <span class="typehead">Elimination:</span> Excreted primarily in the urine. <span class="typehead">Half-Life:</span> 2.4 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects </span></p>
<ul>
<li>	Monitor for and report S&amp;S of significant GI distress, including NV&amp;D.</li>
<li>	Monitor for S&amp;S of hypoglycemia when used in combination with a sulfonylurea drug.</li>
<li>	Lab tests: Periodic fasting and postprandial plasma glucose and periodic HbA1c; baseline and periodic renal function tests.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>	Follow directions for taking this drug (see Administration).</li>
<li>	If a dose is missed, wait for the next scheduled dose.</li>
<li>	Discard any pen that has been in use for greater than 30 d.</li>
<li>	Exenatide may cause decreased appetite and some weight loss. </li>
<li>	Report significant GI distress to physician.</li>
<li>	Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>